FibroGen (NASDAQ:FGEN) Issues Earnings Results

FibroGen (NASDAQ:FGEN) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21, Zacks reports. The business had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the firm earned ($0.52) EPS.

FibroGen Stock Up 2.7 %

Shares of NASDAQ:FGEN opened at $0.34 on Thursday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The stock has a market cap of $34.27 million, a P/E ratio of -0.27 and a beta of 0.72. The business has a fifty day moving average of $0.37 and a two-hundred day moving average of $0.72.

Analyst Ratings Changes

FGEN has been the topic of a number of recent research reports. StockNews.com began coverage on shares of FibroGen in a research report on Thursday. They set a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Wednesday.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.